TY - JOUR
T1 - Utility of the combination of high fluorescence cells and tumor markers for the diagnosis of malignant pleural effusions
AU - Nuez-Zaragoza, Elisa
AU - Bhambi, Indira
AU - Vidal Pla, Monica
AU - Aparicio-Calvente, Isabel
AU - Escoda Giralt, Maria Rosa
AU - Gallardo-Campos, Joana
AU - Ferreres Piñas, Joan Carles
AU - Frisancho, Luis
AU - Mas-Maresma, Laia
AU - Aguilera-Fernandez, Patricia
AU - Marco-Continente, Sonia
AU - Sierra-Boada, Marina
AU - Andreu-Cobo, Pablo
AU - Gallego, Miquel
AU - Tapé, Jaume
AU - Aguadero, Vicente
N1 - Copyright © 2025 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
PY - 2025/1/21
Y1 - 2025/1/21
N2 - Background: New diagnostic tools have emerged to assist the traditional diagnosis of malignant pleural effusion (MPE), such as high fluorescence cells (HFc) and tumor markers (TMs), determined by clinical laboratory automated pleural fluid workup. This study aimed to evaluate the diagnostic ability of the combination of HFc and TMs for diagnosing MPE. Methods: We recruited hospitalized patients with pleural effusion at Parc Taulí University Hospital. We collected and analyzed pleural fluid and serum samples in the clinical laboratory, and we sent a sample of pleural fluid to the Pathology Department for cytology workup. We determined the pleural fluid cell count by Sysmex XN-10 and assessed TMs (CEA, CA19.9, and CA15.3) using the ECLIA Cobas e801 Roche in both pleural fluid and serum samples. We established the final MPE diagnosis based on positive cytology and/or positive pleural biopsy. We classified patients based on these final diagnoses and conducted a comparison between variables, along with multivariate logistic regression. Results: The study included 316 pleural effusions from 221 patients recruited. Multivariate logistic regression indicated the most significant predictor variables for MPE were CA15.3 in serum, CEA ratio, and HFc. We calculated two different models: one excluding HFc and one including it, with the latter displaying superior diagnostic ability (area under the curve 0.91). This model could identify 100 % of MPE cases with 30 % specificity at low cut-offs, and higher values could help identify 60 % of MPE cases with 100 % specificity. Conclusions: Per our findings, this model has high diagnostic performance and could serve as a swift, automated, dependable, non-invasive tool for MPE detection.
AB - Background: New diagnostic tools have emerged to assist the traditional diagnosis of malignant pleural effusion (MPE), such as high fluorescence cells (HFc) and tumor markers (TMs), determined by clinical laboratory automated pleural fluid workup. This study aimed to evaluate the diagnostic ability of the combination of HFc and TMs for diagnosing MPE. Methods: We recruited hospitalized patients with pleural effusion at Parc Taulí University Hospital. We collected and analyzed pleural fluid and serum samples in the clinical laboratory, and we sent a sample of pleural fluid to the Pathology Department for cytology workup. We determined the pleural fluid cell count by Sysmex XN-10 and assessed TMs (CEA, CA19.9, and CA15.3) using the ECLIA Cobas e801 Roche in both pleural fluid and serum samples. We established the final MPE diagnosis based on positive cytology and/or positive pleural biopsy. We classified patients based on these final diagnoses and conducted a comparison between variables, along with multivariate logistic regression. Results: The study included 316 pleural effusions from 221 patients recruited. Multivariate logistic regression indicated the most significant predictor variables for MPE were CA15.3 in serum, CEA ratio, and HFc. We calculated two different models: one excluding HFc and one including it, with the latter displaying superior diagnostic ability (area under the curve 0.91). This model could identify 100 % of MPE cases with 30 % specificity at low cut-offs, and higher values could help identify 60 % of MPE cases with 100 % specificity. Conclusions: Per our findings, this model has high diagnostic performance and could serve as a swift, automated, dependable, non-invasive tool for MPE detection.
KW - High fluorescence cells
KW - Tumor markers
KW - Malignant pleural effusion
KW - CEA
KW - CA 15.3
KW - Pleural fluid
UR - https://www.scopus.com/pages/publications/85215549937
UR - https://www.mendeley.com/catalogue/6bb43d56-f155-321c-bd2f-b39da5bf7e1e/
U2 - 10.1016/j.clinbiochem.2025.110888
DO - 10.1016/j.clinbiochem.2025.110888
M3 - Article
C2 - 39848597
SN - 0009-9120
VL - 136
JO - Clinical Biochemistry
JF - Clinical Biochemistry
M1 - 110888
ER -